We can offer the pharmaceutical industry a better understanding of the Dutch institutional framework, the procedures for market access and reimbursement, the negotiations with hospitals, health insurers but also with the Dutch government when the drug is admitted in the lock system. We can help the industry sharpen their strategy. The Lock (sluis) for new medicines
At the same time we do believe that the current regulation is not working that well but alternatives are difficult to implement. We can offer all parties concerned with the development of new pricing systems to promote innovation but also competitive pricing.